The stock of Inogen Inc (NASDAQ:INGN) reached all time high today, Nov, 14 and still has $87.40 target or 40.00% above today’s $62.43 share price. This indicates more upside for the $1.32B company. This technical setup was reported by Barchart.com. If the $87.40 PT is reached, the company will be worth $528.00M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 120,674 shares traded hands. Inogen Inc (NASDAQ:INGN) has risen 35.93% since April 12, 2016 and is uptrending. It has outperformed by 30.95% the S&P500.
Inogen Inc (NASDAQ:INGN) Ratings Coverage
Out of 4 analysts covering Inogen (NASDAQ:INGN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Inogen has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Piper Jaffray initiated Inogen Inc (NASDAQ:INGN) on Thursday, March 24 with “Neutral” rating. The firm has “Buy” rating by Leerink Swann given on Wednesday, August 12. JP Morgan initiated Inogen Inc (NASDAQ:INGN) on Wednesday, July 13 with “Overweight” rating. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, August 12. As per Tuesday, September 22, the company rating was maintained by Stifel Nicolaus. The stock of Inogen Inc (NASDAQ:INGN) earned “Strong Buy” rating by Needham on Wednesday, November 11.
According to Zacks Investment Research, “Inogen, Inc. is a medical technology company. It offers oxygen concentrator, cart, carry bags, backpacks, external battery chargers and universal power supply for obstructive pulmonary disease patients. The Company’s products include Inogen One G3 and Inogen One G2. It sells its products in the United States and internationally. Inogen, Inc. is headquartered in Goleta, California.”
Insitutional Activity: The institutional sentiment decreased to 0.92 in 2016 Q2. Its down 0.52, from 1.44 in 2016Q1. The ratio worsened, as 22 funds sold all Inogen Inc shares owned while 54 reduced positions. 18 funds bought stakes while 52 increased positions. They now own 21.40 million shares or 1.51% more from 21.09 million shares in 2016Q1.
Ahl Ltd Liability Partnership reported 4,961 shares or 0.01% of all its holdings. Schwab Charles Invest Management Inc holds 60,076 shares or 0% of its portfolio. Oppenheimer Company Incorporated has invested 0.02% of its portfolio in Inogen Inc (NASDAQ:INGN). Nationwide Fund Advisors holds 77,139 shares or 0.02% of its portfolio. Fmr Ltd accumulated 400,500 shares or 0% of the stock. Waddell Reed has invested 0.02% of its portfolio in Inogen Inc (NASDAQ:INGN). Redmond Asset Limited Liability Company last reported 16,094 shares in the company. Service Automobile Association has 51,865 shares for 0.01% of their US portfolio. Deutsche Comml Bank Ag has invested 0% of its portfolio in Inogen Inc (NASDAQ:INGN). Rothschild Asset Inc holds 0.08% or 88,502 shares in its portfolio. Gemmer Asset Mgmt Limited Co has 0% invested in the company for 60 shares. Hbk Invs Limited Partnership last reported 26,400 shares in the company. Menta Cap Limited has invested 0.1% of its portfolio in Inogen Inc (NASDAQ:INGN). Zurcher Kantonalbank (Zurich Cantonalbank) last reported 0% of its portfolio in the stock. Sector Pension Board owns 10,300 shares or 0.01% of their US portfolio.
Another recent and important Inogen Inc (NASDAQ:INGN) news was published by Nasdaq.com which published an article titled: “Inogen Reaches Analyst Target Price” on November 14, 2016.
INGN Company Profile
Inogen, Inc., incorporated on November 27, 2001, is a medical technology company. The Firm is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.